24 results

Vascepa – which will be sold as Vazkepa in Europe – reduces harmful blood fats called triglycerides in patients at risk of potentially fatal heart attack or stroke.

Amarin, the Irish biotech that developed a cardiovascular drug out of refined fish oil, is gearing up for a launch in Europe. It will be a further va(...)

Shares in cardiovascular drugmaker Amarin slumped over 70% last night as the company lost a key patent case in Nevada.

Shares in Irish heart drug company Amarin slumped more than 70 per cent last night as the company lost a key court case in Nevada over the patents of (...)

Irish drug company Amarin says sales from Vascepa, its one cardiovascular drug for 2019, will be at or above the upper end of its previous guidance

Irish drug company Amarin says sales from its one cardiovascular drug for 2019 will be at or above the upper end of its previous guidance – indicating(...)

Amarin’s Vascepa has been found to reduce the risk of cardiovascular events in high-risk patients already being treated with statins.

Amarin, the US-based Irish drug development business, said the European Medicines Agency has accepted an application to licence its cardiovascular dru(...)

Amarin: will Vascepa be prescribed as a preventative therapy or one used only when evidence of disease is found?

It would be churlish to try to put a dampener on the Amarin team after a Food and Drug Administration advisory panel voted 16-0 to back a dramatic inc(...)

US medicines regulator, the Food and Drug Administration, has cleared a major increase in the patients that can access a heart drug from small Irish pharma Amarin.

Shares in Amarin jumped on news that it had won the backing of an FDA advisory panel to sell its heart drug Vascepa to a wider group of patients. The(...)

Vascepa is aiming to become the first prescription drug for people at risk of stroke or heart attack who continue to have high levels of harmful blood fats despite being on treatment with statins

Shares in US-listed Irish biotech Amarin surged in New York after it upgraded its profit forecasts. A strong update for the prospects of its cardiova(...)

The FDA grants priority review only to drugs that have the potential to offer significant improvement in the treatment of serious conditions.

Shares in Irish drug company Amarin jumped 14 per cent after its Vascepa drug was fast-tracked for approval as a treatment for reducing the risk of he(...)

US FDA approval would allow Amarin to pitch its fish-oil drug direct to the consumer rather than solely through the medical practitioner channel. File photograph: Getty

Shareholders tuning into Amarin’s annual shareholders’ meeting in Dublin on Monday had plenty to cheer them. Shares in the company have risen more th(...)

Amarin chief executive John Thero: ‘Our guidance is for 50 per cent greater growth over the prior year’

Irish drug company Amarin will seek European approval for its cardiovascular drug Vascepa before the end of the year. The drug is in the process of s(...)

  • 1
  • 2
  • 3
  • Next
  • Last »